Our study demonstrated that targeted inhibition of GSK3β in renal tubules—either through genetic KO or inhibitor treatment—potentiates Nrf2 antioxidant response via a Keap1-independent mechanism to ameliorate renal oxidative stress and attenuate AKI to CKD transition [26]. This evidence concerns the gene NFE2L2 and chronic kidney disease.